Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder
Go back to Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder| (NYSE: ANRO) | Delayed: 30.27 -0.71 (2.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $30.98 | 52 Week High | $ | |||
| Open | $31.32 | 52 Week Low | $ | |||
| Day High | $31.65 | P/E | N/A | |||
| Day Low | $30.08 | EPS | $ | |||
| Volume | 2,199,286 | |||||
